Cargando…

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy

Pulmonary arterial hypertension (PAH) is a rare complication of dasatinib that was approved as a first-line therapy for chronic myelocytic leukemia (CML). A 24-year-old man presenting dyspnea at rest and leg edema was admitted to our hospital. He had been diagnosed with CML and prescribed dasatinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishimori, Makoto, Honjo, Tomoyuki, Kaihotsu, Kenji, Sone, Naohiko, Yoshikawa, Sachiko, Imanishi, Junichi, Nakayama, Kazuhiko, Emoto, Noriaki, Iwahashi, Masanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985094/ https://www.ncbi.nlm.nih.gov/pubmed/29888010 http://dx.doi.org/10.1155/2018/3895197

Ejemplares similares

An Unusual Case of Inferior Vena Cava Thrombosis in a Healthy Male Bodybuilder
por: Imanishi, Junichi, et al.
Publicado: (2018)

Clinical impact of portal vein pulsatility on the prognosis of hospitalized patients with acute heart failure
por: Kuwahara, Naoya, et al.
Publicado: (2023)

Upfront triple combination therapy-induced pulmonary edema in a case of pulmonary arterial hypertension associated with Sjogren's syndrome
por: Takeuchi, Kimikazu, et al.
Publicado: (2017)

Dasatinib-Induced Colitis with Rectal Sparing in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy: Case Report
por: Maat, Zakaria, et al.
Publicado: (2021)

Dasatinib-induced Pulmonary Hypertension
por: Tamura, Yudai, et al.
Publicado: (2022)

Predictors of Long-term Outcomes in Patients With Connective Tissue Disease Associated With Pulmonary Arterial Hypertension
por: Nakayama, Kazuhiko, et al.
Publicado: (2021)

Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy
por: Yassin, Mohamed A, et al.
Publicado: (2015)

Advanced Pulmonary Hypertension Due to Congenital Double-shunt Successfully Treated with Surgical Repair and Up-front Combination Therapy
por: Suto, Makiko, et al.
Publicado: (2019)

RC time (resistance × compliance) is related to residual symptom after pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension
por: Yanaka, Kenichi, et al.
Publicado: (2022)

Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis
por: Adel, Ahmad, et al.
Publicado: (2021)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019)

Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma
por: Hayashino, Kenta, et al.
Publicado: (2022)

Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose
por: Kubota, Kana, et al.
Publicado: (2022)

Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension
por: Jose, Arun, et al.
Publicado: (2017)

Subsequent shunt closure after targeted medical therapy can be an effective strategy for secundum atrial septal defect with severe pulmonary arterial hypertension: two case reports: Strategy for ASD with Severe PAH
por: Taniguchi, Yu, et al.
Publicado: (2013)

High perfusion pressure as a predictor of reperfusion pulmonary injury after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Kinutani, Hiroto, et al.
Publicado: (2015)

When more is more: the role of additional upfront therapy in pulmonary arterial hypertension
por: Niedermeyer, Shannon, et al.
Publicado: (2023)

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia
por: Hong, Ji Hyung, et al.
Publicado: (2015)

Evaluation of microvasculopathy using dual-energy computed tomography in patients with chronic thromboembolic pulmonary hypertension
por: Onishi, Hiroyuki, et al.
Publicado: (2021)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION
por: Cascino, Thomas M., et al.
Publicado: (2021)

Upfront Combination Therapy: Growing the Case to Get Ahead of Pediatric Pulmonary Arterial Hypertension
por: Steffes, Lea C., et al.
Publicado: (2022)

Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension
por: Fazakas, Csilla, et al.
Publicado: (2018)

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report
por: Skride, Andris, et al.
Publicado: (2017)

Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report
por: Toya, Takumi, et al.
Publicado: (2019)

The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
por: Nakayama, Kazuhiko, et al.
Publicado: (2018)

Combination therapy with pulmonary arterial hypertension targeted drugs and immunosuppression can be a useful strategy for sarcoidosis-associated pulmonary hypertension: a case report
por: Sumimoto, Keiko, et al.
Publicado: (2020)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling
por: Wang, Rui, et al.
Publicado: (2022)

Acute Pulmonary Hypertension Crisis after Adalimumab Reduction in Rheumatoid Vasculitis
por: Yamasaki, Gentaro, et al.
Publicado: (2019)

Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension
por: Ryanto, Gusty Rizky Teguh, et al.
Publicado: (2023)

Sequential Hybrid Therapy With Pulmonary Endarterectomy and Additional Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
por: Yanaka, Kenichi, et al.
Publicado: (2018)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
por: Hennigs, Jan K, et al.
Publicado: (2011)

Variables associated with pulmonary hypertension screened by echocardiography in chronic myeloid leukemia patients on dasatinib therapy
por: Jin, Wenying, et al.
Publicado: (2022)

A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities
por: Nekoukar, Zahra, et al.
Publicado: (2021)

Dasatinib suppresses particulate-induced pyroptosis and acute lung inflammation
por: Pan, Yixi, et al.
Publicado: (2023)

Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015)

DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019)

Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation
por: Kumagai, Takashi, et al.
Publicado: (2017)

Pulmonary Endarterectomy and Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension　― Similar Effects on Health-Related Quality of Life ―
por: Tamada, Naoki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9rrobc470poff4e5cm44ufnud0